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Bacille Calmette-Guérin (BCG) is a live-attenuated strain of Mycobacterium bovis 
developed a century ago by repeated subculture. It remains the only vaccine against 
tuberculosis (TB) in use today, and it offers variable protection against the respiratory 
forms of TB responsible for transmission. The principal genetic basis for BCG atten-
uation is the loss of the region of difference 1 (RD1) that includes the genes codifying 
for production and export of the major virulence factor ESAT6. Today more than 13 
TB vaccine candidates are in clinical evaluation. One of these candidates is MTBVAC, 
which is based on a rationally attenuated Mycobacterium tuberculosis clinical isolate 
belonging to modern lineage 4, one of the most widespread lineages among humans. 
MTBVAC conserves most of the T cell epitopes described for TB including the major 
immunodominant antigens ESAT6 and CFP10 of the RD1, deleted in BCG. After almost 
20 years of discovery and preclinical development, MTBVAC is the only live attenuated 
vaccine based on a human pathogen that has successfully entered clinical trials as a 
preventive vaccine in newborns, aiming to replace BCG, and as a preventive vaccine in 
adolescents and adults (BCG-vaccinated at birth). Our recent preclinical studies have 
demonstrated that MTBVAC-induced immunity to ESAT6 and CFP10 correlate with 
improved efficacy relative to BCG encouraging exploration of these responses in human 
clinical trials as potential biomarkers and identification of these antigens as possible 
correlates of vaccine-induced protection. Such data would be extremely valuable as they 
would greatly accelerate clinical development to efficacy trials.
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inTRODUCTiOn
The current tuberculosis (TB) vaccine, Bacille Calmette-Guérin (BCG), is an attenuated strain of 
Mycobacterium bovis based on the etiologic agent of TB in cattle (1). BCG was introduced for the 
first time into clinical use almost a hundred years ago, when in 1921 it was given orally to an infant 
whose mother had died of TB a day after delivery. The infant showed no adverse events to vaccination 
with BCG and importantly, did not develop disseminated TB, the common form of disease at that 
time acquired mainly form unpasteurized milk of infected cows (2).
FiGURe 1 | Genomic deletions between human and cattle tuberculosis pathogens. Eight regions of difference (RD) deleted in the bovine pathogen Mycobacterium 
bovis with respect to the human pathogen Mycobacterium tuberculosis. Repeated subcultivation of an M. bovis strain for 13 years (1908–1921), following classical 
Pasteur’s postulates, led to attenuation due to loss of RD1, giving rise to Bacille Calmette-Guérin (BCG). MTBVAC is the result of the rational attenuation of an M. 
tuberculosis clinical isolate by genetic deletions of the two independent virulence genes phoP and fadD26, following molecular Pasteur’s postulates for attenuated 
vaccines.
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Today, BCG remains the only licensed vaccine against TB, 
given by the intradermal route of administration at birth. In 
infants, BCG is acknowledged to afford substantial protection 
against disseminated (miliary and meningeal) forms of TB (3, 4), 
whereas in adolescents and adults, lack of BCG efficacy against 
respiratory (pulmonary) TB, the most common form of the 
disease responsible for transmission, is considered to be a result 
of waning BCG immunity with time that is gradually lost 10 years 
after vaccination (5).
Tuberculosis has reached alarming proportions of 10.4 mil-
lion incidence cases and 1.7 million deaths attributed to the 
disease as reported by the latest World Health Organization (6) 
global TB report 2017. Globally, some 50 million individuals are 
already latently infected with MDR Mycobacterium tuberculosis 
strains creating a remarkable resource for future cases of active 
TB with insufficient treatment options. Nevertheless, the WHO 
End TB Strategy has vowed to reduce TB morbidity by 90% and 
TB mortality by 95% by 2035 and recognizes the urgent need for 
more accessible diagnostic tools that are rapid and reliable, new 
less toxic and more efficacious antibiotics to shorten therapy and 
ultimately new vaccines to prevent pulmonary TB in order to 
achieve this ambitious goal (7).
There are a total of 12 candidates in the current clinical TB 
vaccine pipeline and they can be classified into three groups (2), 
including preventive pre- and postexposure subunit vaccines: 
viral or subunit vaccines that aim to boost immunity to BCG, 
killed or fractioned whole cell vaccines, and live-attenuated 
mycobacterial vaccines, which target either BCG-replacement at 
birth or prevention of TB in adolescents and adults.
Currently, the most advanced live-attenuated vaccine in 
clinical development is the recombinant BCG VPM1002, which 
is now entering efficacy trials aimed to prevent TB in infants 
with and without HIV exposure (8). The other candidate is the 
live-attenuated M. tuberculosis MTBVAC, which is the first vac-
cine of its kind to successfully enter human clinical evaluation in 
the history of human vaccinology. These two candidates could 
eventually replace BCG, if able to demonstrate improved safety 
and or greater efficacy than BCG when administered in newborns 
in high-burden TB-endemic settings.
The main advantage of using rationally attenuated live 
M. tuberculosis as vaccine is that many genetic regions encoding 
important immunodominant antigens absent in BCG are still 
present in attenuated M. tuberculosis, while chromosomal dele-
tions in virulence genes provide assurance for safety and genetic 
stability (Figure 1). These vaccines are expected to safely induce 
more specific and longer lasting immune responses in humans 
that can provide protection against all forms of the disease (9). 
This is the rationale that has been followed in the development of 
the live-attenuated MTBVAC.
MTBvAC
MTBVAC was constructed by rational attenuation of the 
M. tuberculosis clinical isolate Mt103 (10), belonging to the 
modern M. tuberculosis Lineage 4, which together with Lineage 
2 (Beijing strains) represent the most geographically widespread 
lineages of MTBC transmitted by the aerosol route between 
humans (11). Following the Geneva consensus safety require-
ments for progressing new live attenuated mycobacterial vaccines 
to clinical trials (12, 13), MTBVAC was constructed by generat-
ing two independent stable genetic deletions, without antibiotic 
resistance markers, in the genes phoP and fadD26 encoding two 
major virulence factors (10). The gene phoP encodes the tran-
scription factor of the two-component virulence system PhoPR 
and the gene fadD26 participates in biosynthesis and export 
of phthiocerol dimycocerosates (PDIM), the main virulence-
associated cell-wall lipids of M. tuberculosis (14–16). PhoP has 
been shown to regulate more than 2% of M. tuberculosis genome, 
most of which implicated in virulence (17, 18), and this regula-
tion could be mediated through other transcription factors, e.g., 
TABle 1 | Comparison of Bacille Calmette-Guérin (BCG), MTBVAC, and H37Rv 
properties.
BCG MTBvAC H37Rv
Source virulent  
M. bovis
virulent M. tuberculosis Reference 
lab strain
Attenuation process Subcultivation Deletions in phoP and 
fadD26 virulence genes
None
Number of epitopes • • • • • • • •
Immunogenicity • • • • • • •
Protection • • • • •
Attenuation/safety • • • • • •
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WhiB6 of the ESX-1 system (19) or via non-coding RNAs, such 
as the recently described mcr7 and its role in activating the TAT 
secretion system in MTBVAC leading to over secretion of major 
antigens such as those of the Ag85 complex (20). Other relevant 
virulence genes regulated by PhoP include lipid metabolism 
genes (e.g., pks2, pks3) involved in biosynthesis of the polyketide-
derived acyltrehaloses (DAT, PAT) and sulfolipids, which are 
front-line lipid constituents of the cell wall thought to have a role 
in host immune modulation (21, 22). PhoP also regulates genes 
within ESX-1 (e.g., the espACD locus) implicated in the secretion 
of the major antigen and virulence factor ESAT6, so that phoP-
mutants can produce but are unable to export ESAT6 (23).
Since 2001, rigorous preclinical safety, efficacy and immu-
nogenicity studies of prototype SO2 and final vaccine construct 
MTBVAC were conducted in recognized animal models by inde-
pendent (national and international) laboratories. Both MTBVAC 
and its prototype SO2 vaccine demonstrated to be at least as safe 
as BCG in SCID mice, and to confer greater or equivalent efficacy 
to BCG in different animal models (10, 24–27). SO2 conferred 
greater efficacy than BCG in a high-dose challenge, long-term 
survival experiment in guinea pigs (100% survival in SO2 group 
vs. 33% in the BCG group) (24). In guinea pigs, MTBVAC given 
as boost to BCG demonstrated significantly greater protection 
compared to BCG alone (27). In adult and newborn mouse 
models, MTBVAC conferred improved protection compared to 
BCG (25, 26) (Table 1).
The preclinical data with MTBVAC and SO2 provided a 
proof-of-concept to progress MTBVAC to first-in-human Phase 
1 clinical evaluation. For this purpose, MTBVAC was developed 
and characterized as a freeze-dried vaccine product by the 
Spanish Biopharmaceutical company, Biofabri, in compliance 
with current Good Manufacturing Practices, fulfilling regula-
tory guidelines for assuring the quality, safety and stability, and 
efficacy of BCG freeze-dried vaccine (10).
The first-in-human Phase 1 trial designed to evaluate the 
safety, local tolerance and immunogenicity of three escalating 
dose of MTBVAC relative to BCG, was conducted in healthy, 
BCG-naive, HIV-negative adults. MTBVAC showed excellent 
safety and tolerability profile comparable to BCG. MTBVAC was 
at least as immunogenic as BCG, and at the same dose level as 
BCG, MTBVAC group showed greater frequency of polyfunc-
tional CD4+ central memory T cells. This first Phase 1 trial marks 
a historic milestone in human vaccinology, as for the first time a 
live-attenuated M. tuberculosis vaccine has entered clinical trials 
showing excellent safety profile and differential immunogenicity 
profile compared to BCG supporting clinical development in 
high-burden TB endemic countries. Today MTBVAC follows 
two clinical development pathways, the primary supporting 
disease prevention at birth, as BCG-replacement strategy, and the 
secondary pathway supports prevention of pulmonary disease in 
adolescents and adults.
eSAT6: A DOUBle-eDGeD SwORD
During the in vitro subcultivation process of BCG attenuation 
between 1908 and 1921, more than 100 genes were lost from 
BCG, relative to M. tuberculosis (28). Deletion of the region of 
difference 1 (RD1) region, which encodes the protein secretion 
system ESX-1, is considered the deletion responsible for BCG 
attenuation (28) (Figure  1). In a study by Copin et  al. (29), 
where 1,530 experimentally verified human T cell epitopes were 
compared, it was demonstrated that 23% of the known MTBC 
T cell epitopes are absent in BCG. Despite their low molecular 
weight, the two major virulence factors ESAT6 and CFP10 
encoded in the RD1 and absent in BCG, have been shown to 
contain the greatest number of human T cell epitopes recognized 
by the immune system (29). These data suggest the intensive 
interaction maintained throughout evolution between human 
hosts and these major RD1-encoded antigens of M. tuberculosis, 
which is likely a consequence of the crucial role of these proteins 
in virulence.
The role of ESAT6 in virulence has been demonstrated by 
experiments where complementation of BCG with RD1 restores 
full virulence (30), whereas deletion of RD1 in M. tuberculosis 
strains leads to a profoundly attenuated profile (31). ESAT6 has 
been described to interfere in different host–pathogen interac-
tion processes: ESAT6 inhibits autophagy (32), a crucial cel-
lular mechanism to eliminate intracellular pathogens, including 
mycobacteria (33). There exist strong evidences about the ability 
of ESAT6 to trigger cell death on host cells. A recent study dem-
onstrated the contribution of the ESX-1 system to induce necrosis 
on infected neutrophils, in mechanism meditated by reactive-
oxygen species (34); in addition, ESAT6 results also crucial for the 
bacteria to induce apoptosis on infected macrophages (35, 36), 
an event that provides the pathogen the capacity to spread from 
cell-to-cell maintaining an intracellular status (36), which might 
be important to establish early infection in the absence of initial 
recognition by the immune system (37, 38). During the last years, 
a role of ESAT6 in the escape of M. tuberculosis from the phago-
some to the cytosol has been demonstrated to occur both in vitro 
and in vivo in mouse models of infection. This event has been 
considered relevant for infection outcome as strains unable to 
escape to cytosol have an attenuated phenotype (39–41). ESAT6 
also stimulates the induction of type I interferon responses (42), 
which has been reported by some authors as detrimental for TB 
infection control (43).
Despite its great antigenic capacity, experiments in mice have 
shown that esat6 and cfp10, as well as genes involved in their 
secretion, are highly expressed during different stages of lung 
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infection (26, 44). In contrast, antigenic proteins such as those 
from the Ag85 complex, without an apparent role in virulence, 
have been shown to be downregulated upon infection (26, 45, 
46). Antigen expression following infection might have an impact 
on the peptide repertoire presented by the MHC molecules from 
infected cells, which should be coated with peptides derived from 
the most represented proteins by the bacteria, including ESAT6 
and CFP10, and not from those under expressed as Ag85. Indeed, 
human and mouse data indicate a higher degree of differentiation 
of ESAT6-specific T cells compare to Ag85B, due to the different 
antigen availability (47).
A classical approach for rational vaccine development has 
been the construction of vaccines that target the stimulation of 
a specific immune response against the most abundant proteins 
of the pathogen at each stage of infection. Thus, presence of a 
preexisting immunity against ESAT6 and CFP10 upon pathogen 
encounter with host might allowed rapid recognition of infected 
cells and would increase the probabilities to control infection 
before dissemination. In the particular case of BCG, which lacks 
of ESAT6 and CFP10, complementation of this strain with RD1 
increases substantially its protective efficacy in different animal 
models (48, 49), suggesting that the deficient protection of BCG 
could rest on the absence of these major antigens. In addition, 
some subunit vaccines expressing ESAT6 have demonstrated 
good protection in mice and are currently under clinical evalu-
ation (44). In contrast, the MVA85A vaccine demonstrated no 
improved protection compared to BCG in a phase IIb clinical 
trial, despite the good immunogenic profile shown (50). There are 
multiple reasons that could explain this failure, but it is plausible 
that the T cells reactive to Ag85A generated following boosting 
vaccination deficiently recognized infected cells due to the poor 
representation of Ag85A-derived peptides on cellular surface.
In the case of MTBVAC, this vaccine represents a unique 
candidate in the pipeline of vaccines currently under clinical 
evaluation, as it is the only one containing the whole antigen 
repertoire of M. tuberculosis, including the major antigens 
ESAT6 and CFP10 (28). Recently, we have demonstrated that an 
MTBVAC substrain mutant for these two proteins confers similar 
protection to BCG and lower than MTBVAC parental strain, sug-
gesting a link between vaccine-induced protection and ESAT6/
CFP10-mediated response, which could result in the definition of 
a biomarker for correlates-of-protection of MTBVAC (26).
Data available from MTBVAC-clinical trials indicated a 
significative CFP10-specific response in humans at six months 
post MTBVAC vaccination (26, 51). In this regard, it is crucial to 
elucidate the potential interference of MTBVAC in the quantiF-
ERON (QFT) test used nowadays to discern infected individuals, 
as this assay is based on specific reactogenicity against ESAT6 
and CFP10. Current MTBVAC clinical trials in TB endemic 
countries will be key to define this important question. In case of 
interference, we should be cautious with respect of the interpreta-
tion of the results. A direct translation of our preclinical data to 
humans could indicate that positive individuals to QFT induced 
by vaccination could be protected. The current practices where 
QFT-positive individuals are directly treated with isoniazid could 
be detrimental to identify these potential MTBVAC-mediated 
protection, as MTBVAC is a live vaccine, and therefore, sensitive 
to antibiotics. Interestingly, a recent study describes that mainly 
individuals with a high QFT value (higher than 4 IU/ml) have sig-
nificantly a higher risk of develop active TB, whereas individuals 
with a value between 0.35 and 4 have no more probabilities than 
negative individuals (52). These data probably reveal the need to 
reconsider the cutoff of this assay in order to treat with isoniazid 
only individuals with a real risk to develop TB.
MTBvAC CARRieS THe ePiTOPe 
RePeRTOiRe OF M. TUBERCULOSIS
Pioneering studies exploring the genomic basis behind BCG 
attenuation have identified several genetic regions present in 
M. bovis but deleted in BCG (1) (Figure  1). These deletions 
arose during subcultivation in the laboratory probably because 
the parental M. bovis strain was not subjected to the immune 
pressure of the host and hence it gradually lost virulence factors. 
BCG continued being passaged in the laboratory until lyophi-
lization process was established, resulting in the emergence of 
different BCG “daughter” strains (53). These substrains differ 
in genome polymorphisms and show variable efficacy (54). 
Today, we know that BCG polymorphisms affect the synthesis 
of important virulence factors, such as the phoPR virulence 
regulator or PDIM (55–57) which might explain the different 
efficacy of BCG strains.
It is important to remark that regions lost in BCG strains 
also contain potent antigenic proteins. After an updated analysis 
based on previous studies (29, 58), we found that of the 1,603 
experimentally validated human T  cell epitopes, 433 (27%) 
of them are located in RD regions and absent in BCG Pasteur 
(Figure  2). These epitopes are distributed as follows: RD1 307 
epitopes (19.15%), RD2 59 epitopes (3.68%), RD11 42 epitopes 
(2.62%), RD 7 5 epitopes (0.31%), RD10 and RD14 4 epitopes 
each (0.5%), RD5 3 epitopes (0.19%), RD3, RD8, and RD13 2 
epitopes each (0.36%), and RD4, RD6, and RD9 1 epitope each 
(0.18%). The vast number of epitopes absent in BCG is located 
in only five antigenic proteins: ESAT6 (112 epitopes), CFP10 (95 
epitopes), and PPE68 (79 epitopes) within the RD1 region and 
MPT64 (24 epitopes) and Rv1985c (23 epitopes) within RD2 
(Table 2).
It has been described that Ag85B carries an F140L substitution 
predicted to affect protein stability (29). Moreover, our recent 
results demonstrated that Ag85B is absent in the secreted fraction 
of BCG but not of MTBVAC (26). Ag85B contains 86 epitopes 
which account for up to 5.36% of the total epitope content of 
M. tuberculosis. Remarkably, vaccination of C57BL/6 mice with 
BCG resulted in lack of Ag85B-specific response (26).
Of the whole epitope repertoire of the M. tuberculosis chromo-
some, BCG has lost 519 epitopes during its evolution distributed 
in 433 epitopes in RD regions and 86 epitopes in Ag85B. In 
other words, attenuated vaccines based on the human pathogen 
M. tuberculosis as MTBVAC, contains up to 48% more epitopes 
than BCG and consequently they are expected to produce a 
more robust stimulation of the immune system than BCG. It was 
previously demonstrated that MTBVAC-like vaccines exhibit a 
long-term maintenance of CD4+ T  cell memory compared to 
FiGURe 2 | Localization of 1,603 experimentally demonstrated T cell epitopes (according to http://IEDB.org) in the Mycobacterium tuberculosis H37Rv 
chromosome. Those regions absent in Bacille Calmette-Guérin (BCG) but present in M. tuberculosis are shown by red sectors and the percentage of epitopes 
contained in each region is indicated. Three of these regions (RD1, RD2, and RD11) contain >25% of the total M. tuberculosis epitopes. It is also important to note 
that Ag85B (shown by a yellow sector) produced but not secreted by BCG also contains a high percentage of epitopes. Taken together, these results indicate that 
live attenuated vaccines based on the human pathogen, as MTBVAC, would present almost 40% more T cell epitopes than BCG.
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BCG. Notably, this phenotype is specific of Ag85B since these 
experiments were performed in transgenic mice that exclusively 
respond to the p25 peptide of this protein (59).
MTBVAC not only produces all the antigens present in 
M. tuberculosis but it is also able to secrete some of these 
antigens more efficiently than other vaccines. We recently 
demonstrated that among the PhoP-regulated genes, the more 
tightly regulated region corresponds to a small RNA named 
mcr7. Consequently, mcr7 is absent in phoP mutants such as 
the MTBVAC vaccine. Since mcr7 exert a negative effect over 
translation of tatC, this protein involved in the TAT (Twin 
Arginine Translocation) secretion system exhibit higher 
levels in M. tuberculosis phoP mutants and results in more 
efficient secretion of TAT substrates (20). Among these, we 
found Ag85A (79 epitopes) and Ag85C (5 epitopes). Future 
experiments will demonstrate whether this enhanced antigenic 
secretion translate into more efficient immunity against these 
antigens.
Exploration of animal-adapted species of the MTBC such as 
M. bovis have revealed some epitope polymorphisms compared 
to M. tuberculosis (60) and this list is expected to increase as 
more animal isolates become sequenced. Two recent studies 
have demonstrated that these epitope polymorphisms result in 
differential immune responses (61) or MHC recognition (60). 
Consequently, even if the antigen repertoire from the human 
and the cow pathogen is highly similar, we can hypothesize that a 
TABle 2 | Summary table of described tuberculosis T cell-epitopes present in 
RD regions absent in Bacille Calmette-Guérin (BCG).
RD region Rv number/gene name # epitopes Sum
RD10 Rv0221 1 4
Rv0222 echA1 3
RD13 Rv1255c 1 2
Rv1256c cyp130 1
RD4 Rv1513 1 1
RD3 Rv1582c 2 2
RD14 Rv1769 4 4
RD7 Rv1965 yrbE3B 1 5
Rv1973 1
Rv1977 3






RD9 Rv2074 1 1
RD5 Rv2346c 2 3
Rv2350c pIcB 1




RD6 Rv3427c 1 1
RD8 Rv3617 ephA 2 2
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vaccine for human use will benefit from stimulating the immune 
system with the pathogen from human origin.
COnClUDinG ReMARKS
In the current pipeline of TB vaccine candidates in clinical evalu-
ation, MTBVAC is the only vaccine able to induce CFP10- and 
ESAT6-specific immune responses. What is more, our most 
recent results (26) suggest that these responses could be effec-
tive in protecting from pulmonary TB, which would have an 
evident impact on TB transmission. In support of this hypothesis, 
prospective cohort studies with individuals exposed to patients 
with active TB indicate that persons with latent TB infection 
(i.e., those reactive to CFP10 and ESAT6 stimulation) could be 
more protected against secondary M. tuberculosis infection than 
non-infected people (62). Thus, analysis of CFP10- and ESAT6-
positive cells after vaccination in future clinical efficacy trials with 
MTBVAC would be highly valuable in the search of a possible 
biomarker of protection.
AUTHOR COnTRiBUTiOnS
NA, DM, JG-A, and CM contributed equally in the elaboration 
of the manuscript.
FUnDinG
This work was supported by the Spanish Ministry of Economy 
and Competitiveness [grant number BIO2014-5258P], European 
Commission H2020 program [grant number TBVAC2020 
643381], and Gobierno de Aragón/Fondo Social Europeo.
ReFeRenCeS
1. Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, et  al. 
Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci 
U S A (2007) 104:5596–601. doi:10.1073/pnas.0700869104 
2. Kaufmann SH, Weiner J, Reyn CF. Novel approaches to TB vaccine develop-
ment. Int J Infect Dis (2016) 56:263–67. doi:10.1016/j.ijid.2016.10.018 
3. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. 
The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants 
in the prevention of tuberculosis: meta-analyses of the published literature. 
Pediatrics (1995) 96:29–35. 
4. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tubercu-
lous meningitis and miliary tuberculosis worldwide: a meta-analysis and 
assessment of cost-effectiveness. Lancet (2006) 367:1173–80. doi:10.1016/
S0140-6736(06)68507-3 
5. Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, et  al. 
Systematic review and meta-analysis of the current evidence on the duration 
of protection by bacillus Calmette-Guerin vaccination against tuberculosis. 
Health Technol Assess (2013) 17:1–372, v–vi. doi:10.3310/hta17370 
6. WHO. Global Tuberculosis Report (2017). Available from: http://apps.who.int/
iris/bitstream/10665/259366/1/9789241565516-eng.pdf
7. Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent 
tuberculosis reactivation and their managements. Emerg Microbes Infect 
(2016) 5:e10. doi:10.1038/emi.2016.10 
8. Kaufmann SH, Cotton MF, Eisele B, Gengenbacher M, Grode L, Hesseling 
AC, et al. The BCG replacement vaccine VPM1002: from drawing board to 
clinical trial. Expert Rev Vaccines (2014) 13:619–30. doi:10.1586/14760584.
2014.905746 
9. Scriba TJ, Kaufmann SH, Henri Lambert P, Sanicas M, Martin C, Neyrolles 
O. Vaccination against tuberculosis with whole-cell mycobacterial vaccines. 
J Infect Dis (2016) 214:659–64. doi:10.1093/infdis/jiw228 
10. Arbues A, Aguilo JI, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, 
et al. Construction, characterization and preclinical evaluation of MTBVAC, 
the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. 
Vaccine (2013) 31:4867–73. doi:10.1016/j.vaccine.2013.07.051 
11. Stucki D, Brites D, Jeljeli L, Coscolla M, Liu Q, Trauner A, et al. Mycobacterium 
tuberculosis lineage 4 comprises globally distributed and geographi-
cally restricted sublineages. Nat Genet (2016) 48:1535–43. doi:10.1038/ 
ng.3704 
12. Kamath AT, Fruth U, Brennan MJ, Dobbelaer R, Hubrechts P, Ho MM, et al. 
New live mycobacterial vaccines: the Geneva consensus on essential steps 
towards clinical development. Vaccine (2005) 23:3753–61. doi:10.1016/j.
vaccine.2005.03.001 
13. Walker KB, Brennan MJ, Ho MM, Eskola J, Thiry G, Sadoff J, et al. The second 
Geneva consensus: recommendations for novel live TB vaccines. Vaccine 
(2010) 28:2259–70. doi:10.1016/j.vaccine.2009.12.083 
14. Cox JS, Chen B, Mcneil M, Jacobs  WR Jr. Complex lipid determines tis-
sue-specific replication of Mycobacterium tuberculosis in mice. Nature (1999) 
402:79–83. doi:10.1038/47042 
15. Trivedi OA, Arora P, Vats A, Ansari MZ, Tickoo R, Sridharan V, et al. Dissecting 
the mechanism and assembly of a complex virulence mycobacterial lipid. Mol 
Cell (2005) 17:631–43. doi:10.1016/j.molcel.2005.02.009 
16. Kirksey MA, Tischler AD, Simeone R, Hisert KB, Uplekar S, Guilhot C, et al. 
Spontaneous phthiocerol dimycocerosate-deficient variants of Mycobacterium 
tuberculosis are susceptible to gamma interferon-mediated immunity. Infect 
Immun (2011) 79:2829–38. doi:10.1128/IAI.00097-11 
7
Gonzalo-Asensio et al. MTBVAC against TB Epidemic
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1803
17. Gonzalo-Asensio JÁ. Deciphering the Role of PhoP in Mycobacterium tubercu-
losis Virulence. Doctor en Bioquimica, Universidad de Zaragoza (2006).
18. Gonzalo-Asensio J, Mostowy S, Harders-Westerveen J, Huygen K, Hernandez-
Pando R, Thole J, et  al. PhoP: a missing piece in the intricate puzzle of 
Mycobacterium tuberculosis virulence. PLoS One (2008) 3:e3496. doi:10.1371/
journal.pone.0003496 
19. Solans L, Aguilo N, Samper S, Pawlik A, Frigui W, Martin C, et al. A specific 
polymorphism in Mycobacterium tuberculosis H37Rv causes differential 
ESAT6 expression and identifies WhiB6 as a novel ESX-1 component. Infect 
Immun (2014) 82:3446–56. doi:10.1128/IAI.01824-14 
20. Solans L, Gonzalo-Asensio J, Sala C, Benjak A, Uplekar S, Rougemont J, et al. 
The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion system in 
Mycobacterium tuberculosis. PLoS Pathog (2014) 10:e1004183. doi:10.1371/
journal.ppat.1004183 
21. Gonzalo Asensio J, Maia C, Ferrer NL, Barilone N, Laval F, Soto CY, et al. 
The virulence-associated two-component PhoP-PhoR system controls the 
biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis. J Biol 
Chem (2006) 281:1313–6. doi:10.1074/jbc.C500388200 
22. Chesne-Seck ML, Barilone N, Boudou F, Gonzalo Asensio J, Kolattukudy PE, 
Martin C, et  al. A point mutation in the two-component regulator PhoP-
PhoR accounts for the absence of polyketide-derived acyltrehaloses but not 
that of phthiocerol dimycocerosates in Mycobacterium tuberculosis H37Ra. 
J Bacteriol (2008) 190:1329–34. doi:10.1128/JB.01465-07 
23. Frigui W, Bottai D, Majlessi L, Monot M, Josselin E, Brodin P, et al. Control of 
M. tuberculosis ESAT6 secretion and specific T cell recognition by PhoP. PLoS 
Pathog (2008) 4:e33. doi:10.1371/journal.ppat.0040033 
24. Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, Bordat Y, 
et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenu-
ated than BCG and confers protective immunity against tuberculosis in mice 
and guinea pigs. Vaccine (2006) 24:3408–19. doi:10.1016/j.vaccine.2006.03.017 
25. Aguilo N, Uranga S, Marinova D, Monzon M, Badiola J, Martin C. MTBVAC 
vaccine is safe, immunogenic and confers protective efficacy against 
Mycobacterium tuberculosis in newborn mice. Tuberculosis (Edinb) (2016) 
96:71–4. doi:10.1016/j.tube.2015.10.010 
26. Aguilo N, Gonzalo-Asensio J, Alvarez-Arguedas S, Marinova D, Gomez AB, 
Uranga S, et al. Reactogenicity to major tuberculosis antigens absent in BCG 
is linked to improved protection against Mycobacterium tuberculosis. Nat 
Commun (2017) 8:16085. doi:10.1038/ncomms16085 
27. Clark S, Lanni F, Marinova D, Rayner E, Martin C, Williams A. Revaccination 
of guinea pigs with the live attenuated Mycobacterium tuberculosis vaccine 
MTBVAC improves BCG’s protection against tuberculosis. J Infect Dis (2017) 
216(5):525–33. doi:10.1093/infdis/jix030 
28. Marinova D, Gonzalo-Asensio J, Aguilo N, Martin C. MTBVAC from discov-
ery to clinical trials in tuberculosis-endemic countries. Expert Rev Vaccines 
(2017) 16:565–76. doi:10.1080/14760584.2017.1324303 
29. Copin R, Coscolla M, Efstathiadis E, Gagneux S, Ernst JD. Impact of 
in  vitro evolution on antigenic diversity of Mycobacterium bovis bacillus 
Calmette-Guerin (BCG). Vaccine (2014) 32:5998–6004. doi:10.1016/j.
vaccine.2014.07.113 
30. Pym AS, Brodin P, Brosch R, Huerre M, Cole ST. Loss of RD1 contrib-
uted to the attenuation of the live tuberculosis vaccines Mycobacterium 
bovis BCG and Mycobacterium microti. Mol Microbiol (2002) 46:709–17. 
doi:10.1046/j.1365-2958.2002.03237.x 
31. Lewis KN, Liao R, Guinn KM, Hickey MJ, Smith S, Behr MA, et al. Deletion 
of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guerin 
attenuation. J Infect Dis (2003) 187:117–23. doi:10.1086/345862 
32. Romagnoli A, Etna MP, Giacomini E, Pardini M, Remoli ME, Corazzari M, 
et  al. ESX-1 dependent impairment of autophagic flux by Mycobacterium 
tuberculosis in human dendritic cells. Autophagy (2012) 8:1357–70. 
doi:10.4161/auto.20881 
33. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. 
Autophagy is a defense mechanism inhibiting BCG and Mycobacterium 
tuberculosis survival in infected macrophages. Cell (2004) 119:753–66. 
doi:10.1016/j.cell.2004.11.038 
34. Dallenga T, Repnik U, Corleis B, Eich J, Reimer R, Griffiths GW, et al. M. tuber-
culosis-induced necrosis of infected neutrophils promotes bacterial growth 
following phagocytosis by macrophages. Cell Host Microbe (2017) 22:519–30.
e513. doi:10.1016/j.chom.2017.09.003 
35. Derrick SC, Morris SL. The ESAT6 protein of Mycobacterium tuberculosis 
induces apoptosis of macrophages by activating caspase expression. Cell 
Microbiol (2007) 9:1547–55. doi:10.1111/j.1462-5822.2007.00892.x 
36. Aguilo JI, Alonso H, Uranga S, Marinova D, Arbues A, De Martino A, et al. 
ESX-1-induced apoptosis is involved in cell-to-cell spread of Mycobacterium 
tuberculosis. Cell Microbiol (2013) 15:1994–2005. doi:10.1111/cmi.12169 
37. Davis JM, Ramakrishnan L. The role of the granuloma in expansion 
and dissemination of early tuberculous infection. Cell (2009) 136:37–49. 
doi:10.1016/j.cell.2008.11.014 
38. Aguilo N, Marinova D, Martin C, Pardo J. ESX-1-induced apoptosis during 
mycobacterial infection: to be or not to be, that is the question. Front Cell Infect 
Microbiol (2013) 3:88. doi:10.3389/fcimb.2013.00088 
39. Smith J, Manoranjan J, Pan M, Bohsali A, Xu J, Liu J, et al. Evidence for pore 
formation in host cell membranes by ESX-1-secreted ESAT6 and its role 
in Mycobacterium marinum escape from the vacuole. Infect Immun (2008) 
76:5478–87. doi:10.1128/IAI.00614-08 
40. Simeone R, Bobard A, Lippmann J, Bitter W, Majlessi L, Brosch R, et  al. 
Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host 
cell death. PLoS Pathog (2012) 8:e1002507. doi:10.1371/journal.ppat.1002507 
41. Simeone R, Sayes F, Song O, Groschel MI, Brodin P, Brosch R, et al. Cytosolic 
access of Mycobacterium tuberculosis: critical impact of phagosomal acidifi-
cation control and demonstration of occurrence in vivo. PLoS Pathog (2015) 
11:e1004650. doi:10.1371/journal.ppat.1004650 
42. Wassermann R, Gulen MF, Sala C, Perin SG, Lou Y, Rybniker J, et  al. 
Mycobacterium tuberculosis differentially activates cGAS- and inflam-
masome-dependent intracellular immune responses through ESX-1. Cell Host 
Microbe (2015) 17:799–810. doi:10.1016/j.chom.2015.05.003 
43. McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons 
in infectious disease. Nat Rev Immunol (2015) 15:87–103. doi:10.1038/ 
nri3787 
44. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, et  al. A 
multistage tuberculosis vaccine that confers efficient protection before and 
after exposure. Nat Med (2011) 17:189–94. doi:10.1038/nm.2285 
45. Rogerson BJ, Jung YJ, Lacourse R, Ryan L, Enright N, North RJ. Expression lev-
els of Mycobacterium tuberculosis antigen-encoding genes versus production 
levels of antigen-specific T cells during stationary level lung infection in mice. 
Immunology (2006) 118:195–201. doi:10.1111/j.1365-2567.2006.02355.x 
46. Bold TD, Banaei N, Wolf AJ, Ernst JD. Suboptimal activation of antigen-spe-
cific CD4+ effector cells enables persistence of M. tuberculosis in vivo. PLoS 
Pathog (2011) 7:e1002063. doi:10.1371/journal.ppat.1002063 
47. Moguche AO, Musvosvi M, Penn-Nicholson A, Plumlee CR, Mearns H, 
Geldenhuys H, et  al. Antigen availability shapes T  cell differentiation and 
function during tuberculosis. Cell Host Microbe (2017) 21:695–706.e695. 
doi:10.1016/j.chom.2017.05.012 
48. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, et  al. 
Recombinant BCG exporting ESAT6 confers enhanced protection against 
tuberculosis. Nat Med (2003) 9:533–9. doi:10.1038/nm859 
49. Groschel MI, Sayes F, Shin SJ, Frigui W, Pawlik A, Orgeur M, et al. Recombinant 
BCG expressing ESX-1 of Mycobacterium marinum combines low virulence 
with cytosolic immune signaling and improved TB protection. Cell Rep (2017) 
18:2752–65. doi:10.1016/j.celrep.2017.02.057 
50. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, 
et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants 
previously vaccinated with BCG: a randomised, placebo-controlled phase 2b 
trial. Lancet (2013) 381:1021–8. doi:10.1016/S0140-6736(13)60177-4 
51. Spertini F, Audran R, Chakour R, Karoui O, Steiner-Monard V, Thierry AC, 
et  al. Safety of human immunisation with a live-attenuated Mycobacterium 
tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. 
Lancet Respir Med (2015) 3:953–62. doi:10.1016/S2213-2600(15)00435-X 
52. Andrews JR, Nemes E, Tameris M, Landry BS, Mahomed H, Mcclain JB, 
et al. Serial QuantiFERON testing and tuberculosis disease risk among young 
children: an observational cohort study. Lancet Respir Med (2017) 5:282–90. 
doi:10.1016/S2213-2600(17)30060-7 
53. Tran V, Liu J, Behr MA. BCG vaccines. Microbiol Spectr (2014) 2:MGM2–28. 
doi:10.1128/microbiolspec.MGM2-0028-2013 
54. Zhang L, Ru HW, Chen FZ, Jin CY, Sun RF, Fan XY, et al. Variable virulence 
and efficacy of BCG vaccine strains in mice and correlation with genome 
polymorphisms. Mol Ther (2016) 24:398–405. doi:10.1038/mt.2015.216 
8
Gonzalo-Asensio et al. MTBVAC against TB Epidemic
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1803
55. Liu J, Tran V, Leung AS, Alexander DC, Zhu B. BCG vaccines: their mecha-
nisms of attenuation and impact on safety and protective efficacy. Hum Vaccin 
(2009) 5:70–8. doi:10.4161/hv.5.2.7210 
56. Gonzalo-Asensio J, Malaga W, Pawlik A, Astarie-Dequeker C, Passemar C, 
Moreau F, et  al. Evolutionary history of tuberculosis shaped by conserved 
mutations in the PhoPR virulence regulator. Proc Natl Acad Sci U S A (2014) 
111:11491–6. doi:10.1073/pnas.1406693111 
57. Broset E, Martin C, Gonzalo-Asensio J. Evolutionary landscape of the 
Mycobacterium tuberculosis complex from the viewpoint of PhoPR: implica-
tions for virulence regulation and application to vaccine development. MBio 
(2015) 6:e1289–1215. doi:10.1128/mBio.01289-15 
58. Zhang W, Zhang Y, Zheng H, Pan Y, Liu H, Du P, et al. Genome sequencing 
and analysis of BCG vaccine strains. PLoS One (2013) 8:e71243. doi:10.1371/
journal.pone.0071243 
59. Nambiar JK, Pinto R, Aguilo JI, Takatsu K, Martin C, Britton WJ, et  al. 
Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium 
tuberculosis is associated with sustained generation of CD4+ T-cell memory. 
Eur J Immunol (2012) 42:385–92. doi:10.1002/eji.201141903 
60. Yruela I, Contreras-Moreira B, Magalhaes C, Osorio NS, Gonzalo-Asensio J. 
Mycobacterium tuberculosis complex exhibits lineage-specific variations 
affecting protein ductility and epitope recognition. Genome Biol Evol (2016) 
8:3751–64. doi:10.1093/gbe/evw279 
61. Coscolla M, Copin R, Sutherland J, Gehre F, De Jong B, Owolabi O, et  al. 
M. tuberculosis T cell epitope analysis reveals paucity of antigenic variation 
and identifies rare variable TB antigens. Cell Host Microbe (2015) 18:538–48. 
doi:10.1016/j.chom.2015.10.008 
62. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk 
of progression to active tuberculosis following reinfection with Mycobacterium 
tuberculosis. Clin Infect Dis (2012) 54:784–91. doi:10.1093/cid/cir951 
Conflict of Interest Statement: CM and JG-A are coinventors of the patent “tuber-
culosis vaccine” owned by the University of Zaragoza and licensed in exclusivity 
to Biofabri. CM and NA are coinventors of the patent “Inactivated tuberculosis 
vaccine” filled by the University of Zaragoza and Biofabri. The authors have no 
other relevant affiliations or financial involvement with any organization or entity 
with a financial interest in or financial conflict with the subject matter or materials 
discussed in the manuscript apart from those disclosed.
The reviewer CH and handling editor declared their shared affiliation.
Copyright © 2017 Gonzalo-Asensio, Marinova, Martin and Aguilo. This is 
an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
